Science ❯ Biotechnology ❯ Drug Development
PACAP/VIP Monoclonal Antibodies Clustering Antibodies
The merger shifts Fulcrum's remaining capital into Slate's PACAP-targeting migraine program with financing sized to fund development into 2029
